crossover randomized trial

S003172

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Other conditionsS003172

Design

Randomized: 86
Start year
Treatment: 0.4 weeks
Countries
Sponsor: (industry)
Eligibility: healthy adults 18 to 65 years; BMI 25 to 35 kg/m2; fasting glucose below 110 mg/dL

Conduct and analysis

Blinding: double blind
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population: completers
Missing data: completers only

Arms

Arm	Treatment	Background	Randomized	Analyzed
A1	exenatide Exenatide IV infusion	lifestyle: not reported	86	74
A2	Placebo Placebo IV infusion	lifestyle: not reported	86	74
A3	Moxifloxacin Moxifloxacin 400 mg oral	lifestyle: not reported	86	74

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Whole trial ALL
age	mean (years)	42
age	sd (years)	12
bmi	mean (kg/m2)	28.4
bmi	sd (kg/m2)	2.3
other male	percent	91
white	percent	73

Results

6 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

Serious adverse events (3 lines; O25)

Arm	Statistic	Events / N	Detail
A1	events	0 / 86	not stated; safety; R0026444:Results
A2	events	0 / 86	not stated; safety; R0026444:Results
A3	events	0 / 86	not stated; safety; R0026444:Results

Death by suicide (3 lines; O35B)

Arm	Statistic	Events / N	Detail
A1	events	0 / 86	not stated; safety; R0026444:Results
A2	events	0 / 86	not stated; safety; R0026444:Results
A3	events	0 / 86	not stated; safety; R0026444:Results